RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
CRISPR Therapeutics - Stock

CRISPR Therapeutics EBIT 2024

CRISPR Therapeutics EBIT

-523.31 M USD

CRISPR Therapeutics Dividend yield

Ticker

CRSP

ISIN

CH0334081137

WKN

A2AT0Z

In 2024, CRISPR Therapeutics's EBIT was -523.31 M USD, a 135.16% increase from the -222.54 M USD EBIT recorded in the previous year.

The CRISPR Therapeutics EBIT history

YEAREBIT (undefined USD)
2030e3.77
2029e2.12
2028e0.42
2027e0.09
2026e-0.12
2025e-0.42
2024e-0.52
2023-0.22
2022-0.67
20210.37
2020-0.35
20190.05
2018-0.16
2017-0.06
2016-0.07
2015-0.03
2014-0.01

CRISPR Therapeutics Aktienanalyse

What does CRISPR Therapeutics do?

CRISPR Therapeutics AG is a company specializing in the development of therapies based on the gene editing technology CRISPR-Cas9. The company was founded in 2013 in Basel, Switzerland and is now headquartered in Zug, Switzerland. CRISPR Therapeutics is listed on the NASDAQ stock exchange and also has offices in the USA and London. CRISPR Therapeutics AG's history is closely linked to the discovery and development of the CRISPR-Cas9 technology. This revolutionary technique allows for the targeted modification, repair or elimination of certain genes in the genome of organisms. The technology was first discovered in the 1990s, but it was only in recent years with the development of CRISPR-Cas9 that it became possible to apply this technique in medical research. The goal of CRISPR Therapeutics AG is to use the CRISPR-Cas9 technology to develop therapies for life-threatening genetic diseases. The company works closely with the academic community and industry to develop innovative therapies and bring them through clinical trials. The business model of CRISPR Therapeutics AG is based on the development and commercialization of therapies based on the CRISPR-Cas9 technology. This involves using the technology to treat the genetic causes of serious diseases such as cystic fibrosis, sickle cell anemia, beta-thalassemia, or certain types of cancer. The company has a number of products in its pipeline and works closely with partners such as Vertex Pharmaceuticals and Bayer. CRISPR Therapeutics operates in the biotechnology industry and is divided into various divisions. For example, there is the research and development (R&D) division, which focuses on developing new therapies based on the CRISPR-Cas9 technology. Here, the company works on its own research projects as well as joint research projects with partners. There is also a clinical studies department that aims to test new therapies, prove their efficacy and safety in humans, and produce approved therapeutics. An example of a current product from the company is the CTX001 therapy, which involves stem cell transplantation using genetically modified stem cells from healthy donors to produce genetically error-free blood cells in the patient's body. CTX001 is currently in phase 1/2a clinical trials for the treatment of beta-thalassemia and sickle cell anemia, and is being jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals. In summary, CRISPR Therapeutics AG is a company in the biotechnology industry specializing in the development and commercialization of therapies based on the CRISPR-Cas9 technology. The company has a number of products in its pipeline and works closely with partners to develop innovative therapies and bring them through clinical trials. With the CRISPR-Cas9 technology, there is the potential to combat genetic diseases, which could have a significant impact on the treatment of diseases in the future. CRISPR Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing CRISPR Therapeutics's EBIT

CRISPR Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of CRISPR Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

CRISPR Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in CRISPR Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about CRISPR Therapeutics Stock

How much did CRISPR Therapeutics achieve in EBIT for the current year?

In the current year, CRISPR Therapeutics has achieved an EBIT of -523.31 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company CRISPR Therapeutics.

How has the EBIT of CRISPR Therapeutics developed in recent years?

The EBIT of CRISPR Therapeutics has increased by 135.156% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company CRISPR Therapeutics?

The EBIT of CRISPR Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does CRISPR Therapeutics pay?

Over the past 12 months, CRISPR Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CRISPR Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of CRISPR Therapeutics?

The current dividend yield of CRISPR Therapeutics is .

When does CRISPR Therapeutics pay dividends?

CRISPR Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CRISPR Therapeutics?

CRISPR Therapeutics paid dividends every year for the past 0 years.

What is the dividend of CRISPR Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CRISPR Therapeutics located?

CRISPR Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von CRISPR Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CRISPR Therapeutics from 6/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/5/2024.

When did CRISPR Therapeutics pay the last dividend?

The last dividend was paid out on 6/5/2024.

What was the dividend of CRISPR Therapeutics in the year 2023?

In the year 2023, CRISPR Therapeutics distributed 0 USD as dividends.

In which currency does CRISPR Therapeutics pay out the dividend?

The dividends of CRISPR Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CRISPR Therapeutics

Our stock analysis for CRISPR Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CRISPR Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.